Grant Collaborations

Collaborate to Accelerate COPD Innovation

GattyInstruments AB (GIAB) forms partnerships, builds consortia, and contributes to collaborative projects in COPD prevention, early detection, monitoring, and care pathway improvement.

We work with healthcare providers, researchers, community organisations, and industry partners to develop evidence-based proposals and deliver projects in real-world settings.

If you are exploring a COPD-related grant or looking to join a consortium, we welcome structured discussions on roles, scope, and delivery. 

How We Collaborate

GIAB collaborates with healthcare providers, researchers, and industry leaders to drive advancements in COPD care.
We welcome opportunities to join grants and consortia for meaningful, real-world solutions.

Consortium Building

We help define roles, align partner strengths, and structure a deliverable work plan for competitive calls.

Grant Strategy & Fit

We map project ideas to call requirements, eligibility rules, and expected outputs to reduce proposal risk.

Proposal Coordination

We coordinate inputs, timelines, compliance checks, and final assembly to strengthen clarity and consistency.

Project Delivery Focus

We ensure governance, reporting, and planning to move from concept to execution.

Evidence & Communication

We refine project narratives, impact logic, and dissemination plans for funders and stakeholders.

Partner Type We Seek

We seek partners across healthcare, research, and industry to create impactful solutions for COPD.
Together, we aim to drive meaningful progress through collaborative expertise and shared goals.

Healthcare and Clinical Partners

  • Outpatient clinics and specialist units (real-world testing and feedback) 
  • Primary care and rehabilitation providers (implementation pathways) 
  • Care pathway owners and procurement stakeholders (adoption readiness) 

Academic & Research Partners

  • Clinical and translational research teams (study design, outcomes, evaluation) 
  • Implementation research groups (feasibility, workflow integration, uptake) 
  • Health data science teams (analysis, modelling, and evaluation support) 

Community & Civil Society Partners

  • Patient and caregiver organisations (needs validation, engagement, co-design) 
  • Community organisations (reach and adoption in real-life settings) 

Industry & Technology Partners

  • Sensor, wearable, or digital health solution providers (complementary capabilities
  • Data platform and integration partners (data handling and analytics support) 
  • SMEs and innovators building COPD-related solutions (joint proposals) 

Why Partner with Us

Partnering with us means leveraging expertise, resources, and a collaborative approach to drive impactful COPD solutions.
Together, we turn ideas into actionable, real-world outcomes.

Partner-Centric Collaboration

Clear, partner-friendly collaboration approach focused on roles, deliverables, and realistic execution.

Multi Country Expertise

Experience working in multi-country projects and consortia environments (as evidenced by our project portfolio).

Home Monitoring Focus

Commitment to outpatient and home monitoring settings where practical adoption matters.

Implementation Clarity

Focus on proposal clarity, compliance discipline, and credible implementation pathways.

Our Projects

Active Project

AIRBEST

Consortium website: airbest-copd.com

Purpose

Advancing technologies in respiratory diagnostics to support early detection and management of respiratory conditions.

Role

Coordinator

What We Do

  • Participate in an international consortium focused on respiratory diagnostics innovation. 
  • Contribute to project activities aligned with developing next-generation exhaled breath measurement for COPD detection. 

Partner Opportunities

  • Partners with complementary respiratory diagnostics expertise or validation capacity for future projects. 
  • Organisations interested in joint applications targeting COPD early detection and monitoring. 

Chronic obstructive pulmonary disease (COPD) is a lung disease that affects the airways. The most common causes of COPD are smoking and pollution. COPD is the most common and fourth leading cause of death worldwide. According to a WHO report, approximately 3.5 million deaths occurred in 2021.

AIRBEST is an EUREKA-Eurostars project focused on advancing technologies in respiratory diagnostics. The project aims to enable individuals to monitor their health. It holds potential for improving the early detection and management of respiratory conditions, ultimately enhancing overall health.

The AIRBEST initiative unites an esteemed international consortium of technology specialists and innovative SMEs to enhance diagnostics for COPD patients.

Partners

Project Aim

The AIRBEST project aims to develop a next-generation exhaled breath-measuring instrument that accurately detects and informs users and healthcare providers about COPD.

Project Objective

To develop an advance diagnostic instrument for the detection of lung disease.

Project Overview

  • Budget: 1.5M Euro
  • Duration: 3 Years
  • Partners: 3
  • Countries: France and Sweden

Past Project

Masimo

Purpose

Pre-study of next-generation exhaled breath sensors and systems.

Role

Consultant

What We Do

Consulting project from June 2021 – December 2023.

Project Title

System and methods for Continuously Monitoring a Concentration of Volatile Breathing Compounds (Publication number: 20260014333)

Inventor

  • Fernkvist, Per
  • Gatty, Hithesh Kumar

Filing Date

02 Feb 2025

Publication Date

15 Jan 2026

Active Project

C-COPE - Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (“MultiPMData2026”)

Purpose

Evaluating a multimodal digital monitoring and early-warning approach for COPD–CVD multimorbidity following AECOPD.

Role

To be confirmed.

What We Do

  • Work on an integrated approach combining home lung-function monitoring with exhaled carbon monoxide, cardio-respiratory remote monitoring via a wearable wristband with environmental data access, wrist-based ECG for heart rate and rhythm assessment including atrial fibrillation detection, and a prediction platform integrating sensor data, patient-reported outcomes, environmental exposures, and clinical history. 
  • Support testing in real-world outpatient and home-monitoring settings across Sweden and Türkiye. 
  • Contribute to implementation-ready evidence for personalised early-warning systems in COPD–CVD care pathways. 

Partner Opportunities

  • Clinical and care partners interested in outpatient and home-monitoring evaluation settings. 
  • Research teams supporting implementation evaluation, feasibility, and patient engagement approaches. 
  • Technology/data partners supporting integration and analysis within project constraints. 
Work Plan Diagram

C-COPE addresses a critical gap in personalized multimorbidity care: the sharp, short-term rise in cardiovascular disease (CVD) events following acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Evidence shows that for patients with COPD and established CVD, the first 1–7 days after an AECOPD episode constitute a peak window of preventable cardiovascular risk, with increased incidence of myocardial infarction, heart-failure decompensation, arrhythmias, stroke, hospitalization, and early mortality. Current care pathways remain largely reactive, identifying deterioration only after symptom escalation or emergency presentation.

C-COPE aims to close this gap through a personalized, multimodal digital monitoring and early-warning system for outpatient and home use that predicts and mitigates cardiovascular deterioration triggered by AECOPD. The project will evaluate an integrated solution combining home lung-function monitoring with exhaled carbon monoxide, CE-marked cardio-respiratory remote monitoring via a wearable wristband with environmental data access, wrist-based ECG for heart rate and rhythm assessment including atrial fibrillation detection, and an explainable prediction platform integrating sensor data, patient-reported outcomes, environmental exposures, and clinical history. Earlier detection of pre-symptomatic physiological changes enables timely clinical review during the highest-risk period, supporting proactive management of COPD–CVD multimorbidity.

Testing will take place in real-world outpatient and home-monitoring settings across Sweden and Türkiye. Expected outcomes include validated predictors of AECOPD-related cardiovascular vulnerability, demonstrated feasibility of the integrated solution, improved patient engagement, and implementation-ready evidence for personalized early-warning systems in COPD–CVD care pathways.

Total Project Cost

€1,135,357

Total Requested Budget

€870,838

Project Duration

36 months

Let’s Advance COPD Research Together

Advancing solutions for Chronic Obstructive Pulmonary Disease (COPD) requires strong, multidisciplinary partnerships. We collaborate with healthcare providers, researchers, community organizations, and industry partners to develop innovative, evidence-based grant proposals that improve prevention, early detection, treatment, and patient outcomes.

What to include in your message 

  • Your organisation type (clinic, university, SME, community organisation, etc.) 
  • Country and eligibility constraints you must follow (if known) 
  • What you can contribute (clinical site, evaluation, data science, technology, community access) 
  • Which calls or programmes you are targeting (or your preferred timeline) 
  • Your proposed role and what you are looking for from the consortium 

Interested in partnering on a COPD-related grant? Let’s stay in touch to explore collaboration opportunities.

What We Do

Collaborate to Accelerate COPD Innovation

We form partnerships, build consortia and lead projects in our fields of expertise, …

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

What We Do

Collaborate to Accelerate COPD Innovation

We form partnerships, build consortia and lead projects in our fields of expertise, …

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

What We Do

Collaborate to Accelerate COPD Innovation

We form partnerships, build consortia and lead projects in our fields of expertise, …

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

AIRBEST

Chronic obstructive pulmonary disease (COPD) is a lung disease that affects the airways. The most common causes of COPD are smoking and pollution. COPD is the most common and fourth leading cause of death worldwide. According to a WHO report, approximately 3.5 million deaths occurred in 2021. AIRBEST is an EUREKA-Eurostars project focused on advancing technologies in respiratory diagnostics. The project aims to enable individuals to monitor their health. It holds potential for improving the early detection and management of respiratory conditions, ultimately enhancing overall health. The AIRBEST initiative unites an esteemed international consortium of technology specialists and innovative SMEs to enhance diagnostics for COPD patients.

Project Aim

The AIRBEST project aims to develop a next-generation exhaled breath-measuring instrument that accurately detects and informs users and healthcare providers about COPD.

Project Objective

To develop an advance diagnostic instrument for the detection of lung disease.

Project Overview

  • Budget: 1.5M Euro
  • Duration: 3 Years
  • Partners: 3
  • Countries: France and Sweden